Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma - Shen, Y-C; Ou, D-L; Hsu, C; Lin, K-L; Chang, C-Y; Lin, C-Y; Liu, S-H; Cheng, A-L (British journal of cancer, 2013)
Keywords: 631/67/1059/2326; 692/53/2423; 692/699/67/1504/1610; Adenosine triphosphate; Animals; Apoptosis; Bioenergetics; Biological and medical sciences; Biomarkers; Biomedical and Life Sciences; Biomedicine; Cancer Research; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - metabolism; Cell Line, Tumor; Dehydrogenases; Drug Resistance; Drug Resistance, Neoplasm; Epidemiology; Gastroenterology. Liver. Pancreas. Abdomen; Glucose; Glycolysis; Hospitals; Humans; Kinases; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - metabolism; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Medical research; Medical sciences; Medicine; Metabolism; Mice; Mitochondrial DNA; Molecular Medicine; Niacinamide - analogs & derivatives; Oncology; Oxidative Phosphorylation; Phenylurea Compounds; Phosphorylation; Protein-Serine-Threonine Kinases - antagonists & inhibitors; Translational Therapeutics; Tumors; Xenograft Model Antitumor Assays; United States--US; Taiwan; dichloroacetate; sorafenib; oxidative phosphorylation; hepatocellular carcinoma; glycolysis; Antineoplastic agent; Pyruvate kinase; Enzyme; Tyrosine kinase inhibitor; Transferases; Pyruvate dehydrogenase (lipoamide); Enzyme inhibitor; Hepatic disease; Hepatocellular carcinoma; Malignant tumor; Resistance; Liver cancer; Cancerology; Oxidative phosphorylation; Sorafenib; Glycolysis; Digestive diseases; Multikinase inhibitor; Oxidoreductases; Antiangiogenic agent; Cancer